Oridis Licenses Tissue Microarray Technology

Oridis Biomed (Graz, Austria), a biopharmaceutical company, announced that it has entered into a license agreement with the National Institutes of Health (NIH, Bethesda, MD, USA) for the worldwide commercial use of NIH's proprietary tissue microarray (TMA).

TMAs are a tool within Oridis Biomed's Tissomics platform, which permits the rapid and simultaneous study of several hundred tissue samples, using standardized high-throughput analysis by in-house pathologists.

"We are pleased to have been granted by the NIH a license for this TMA technology”, said Georg Casari, Ph.D., head of Oridis Biomed's Tissomics business. "This license agreement further strengthens our Tissomics business for the life-science industry worldwide, where we offer our clients the ability to validate their research, such as biomarker and target verification programs.”

Oridis Biomed commercializes its proprietary Tissomics platform in collaboration with industrial partners, as well as its own research and development programs. The company is developing diagnostics, biomarkers (targeted treatment solutions), and therapeutics for liver diseases. Therapeutic programs include primary liver cancer (hepatocellular carcinoma, HCC) and metabolic liver diseases, such as alcoholic steatohepatitis (ASH) and non- alcoholic steatohepatitis (NASH), where incidence rates are rapidly increasing, while treatment options are limited, expensive, and often ineffective.



Related Links:
Oridis Biomed
National Institutes of Health